U.S. Diabetic Retinopathy Market Size, Share & Trends Analysis Report By Type (Proliferative DR, Non-proliferative DR), By Management (Anti-VEGF Therapy, Vitrectomy), And Segment Forecasts, 2024 - 2030

Table of Contents

Chapter 1. U.S. Diabetic Retinopathy Market: Methodology and Scope
                   1.1. Market Segmentation & Scope
                   1.2. Segment Definitions
                       1.2.1. Type
                       1.2.2. Management
                       1.2.3. Regional scope
                       1.2.4. Estimates and forecasts timeline
                   1.3. Research Methodology
                   1.4. Information Procurement
                       1.4.1. Purchased database
                       1.4.2. GVR’s internal database
                       1.4.3. Secondary sources
                       1.4.4. Primary research
                       1.4.5. Details of primary research
                           1.4.5.1. Data for primary interviews in North America
                           1.4.5.2. Data for primary interviews in Europe
                           1.4.5.3. Data for primary interviews in Asia Pacific
                           1.4.5.4. Data for primary interviews in Latin America
                           1.4.5.5. Data for Primary interviews in MEA
                   1.5. Information or Data Analysis
                       1.5.1. Data analysis models
                   1.6. Market Formulation & Validation
                   1.7. Model Details
                       1.7.1. Commodity flow analysis (Model 1)
                       1.7.2. Approach 1: Commodity flow approach
                       1.7.3. Volume price analysis (Model 2)
                       1.7.4. Approach 2: Volume price analysis
                   1.8. List of Secondary Sources
                   1.9. List of Primary Sources
                   1.10. Objectives
Chapter 2. U.S. Diabetic Retinopathy Market: Executive Summary
                   2.1. Market Outlook
                   2.2. Segment Outlook
                       2.2.1. Type outlook
                       2.2.2. Management outlook
                       2.2.3. Regional outlook
                   2.3. Competitive Insights
Chapter 3. U.S. Diabetic Retinopathy Market: Variables, Trends & Scope
                   3.1. Market Lineage Outlook
                       3.1.1. Parent market outlook
                       3.1.2. Related/ancillary market outlook
                   3.2. Market Dynamics
                       3.2.1. Market driver analysis
                           3.2.1.1. Increasing prevalence of diabetes
                           3.2.1.2. Growing geriatric population
                           3.2.1.3. Increasing prevalence of blindness due to diabetes
                       3.2.2. Market restraint analysis
                           3.2.2.1. Lack of accurate diagnosis
                           3.2.2.2. Adverse effect on treatment
                   3.3. U.S. Diabetic Retinopathy Market Analysis Tools
                       3.3.1. Industry Analysis - Porter’s
                           3.3.1.1. Supplier power
                           3.3.1.2. Buyer power
                           3.3.1.3. Substitution threat
                           3.3.1.4. Threat of new entrant
                           3.3.1.5. Competitive rivalry
                       3.3.2. PESTEL Analysis
                           3.3.2.1. Political landscape
                           3.3.2.2. Economic landscape
                           3.3.2.3. Social landscape
                           3.3.2.4. Technological landscape
                           3.3.2.5. Environmental landscape
                           3.3.2.6. Legal landscape
Chapter 4. U.S. Diabetic Retinopathy Market: Type Estimates & Trend Analysis
                   4.1. Type Market Share, 2023 & 2030
                   4.2. Segment Dashboard
                   4.3. U.S. Diabetic Retinopathy Market by Type Outlook
                   4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
                       4.4.1. Proliferative Diabetic Retinopathy
                           4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       4.4.2. Non-proliferative Diabetic Retinopathy
                           4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. U.S. Diabetic Retinopathy Market: Management Estimates & Trend Analysis
                   5.1. Management Market Share, 2023 & 2030
                   5.2. Segment Dashboard
                   5.3. U.S. Diabetic Retinopathy Market by Management Outlook
                   5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
                       5.4.1. Anti-VEGF
                           5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       5.4.2. Intraocular Steroid Injection
                           5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       5.4.3. Laser Surgery
                           5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       5.4.4. Vitrectomy
                           5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
                   7.1. Recent Developments & Impact Analysis, By Key Market Participants
                   7.2. Company/Competition Categorization
                   7.3. Vendor Landscape
                       7.3.1. List of key distributors and channel partners
                       7.3.2. Key customers
                       7.3.3. Key company market share analysis, 2023
                       7.3.4. Bayer AG
                           7.3.4.1. Company overview
                           7.3.4.2. Financial performance
                           7.3.4.3. Product benchmarking
                           7.3.4.4. Strategic initiatives
                       7.3.5. ABBVIE INC.
                           7.3.5.1. Company overview
                           7.3.5.2. Financial performance
                           7.3.5.3. Product benchmarking
                           7.3.5.4. Strategic initiatives
                       7.3.6. Novartis AG
                           7.3.6.1. Company overview
                           7.3.6.2. Financial performance
                           7.3.6.3. Product benchmarking
                           7.3.6.4. Strategic initiatives
                       7.3.7. Oxurion NV
                           7.3.7.1. Company overview
                           7.3.7.2. Financial performance
                           7.3.7.3. Product benchmarking
                           7.3.7.4. Strategic initiatives
                       7.3.8. Sirnaomics
                           7.3.8.1. Company overview
                           7.3.8.2. Financial performance
                           7.3.8.3. Product benchmarking
                           7.3.8.4. Strategic initiatives
                       7.3.9. Alimera Sciences
                           7.3.9.1. Company overview
                           7.3.9.2. Financial performance
                           7.3.9.3. Product benchmarking
                           7.3.9.4. Strategic initiatives
                       7.3.10. Ampio Pharmaceuticals Inc.
                           7.3.10.1. Company overview
                           7.3.10.2. Financial performance
                           7.3.10.3. Product benchmarking
                           7.3.10.4. Strategic initiatives
                       7.3.11. BCNPeptides
                           7.3.11.1. Company overview
                           7.3.11.2. Financial performance
                           7.3.11.3. Product benchmarking
                           7.3.11.4. Strategic initiatives
                       7.3.12. Kowa Company Ltd.
                           7.3.12.1. Company overview
                           7.3.12.2. Financial performance
                           7.3.12.3. Product benchmarking
                           7.3.12.4. Strategic initiatives
                       7.3.13. Genentech, Inc.
                           7.3.13.1. Company overview
                           7.3.13.2. Financial performance
                           7.3.13.3. Product benchmarking
                           7.3.13.4. Strategic initiatives

List of Tables

Table 1 List of Abbreviation
Table 2 U.S. diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 3 U.S. diabetic retinopathy market, by management, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 U.S. Diabetic retinopathy market: Market outlook
Fig. 14 U.S. Diabetic retinopathy market competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Penetration and growth prospect mapping
Fig. 18 Industry value chain analysis
Fig. 19 U.S. Diabetic retinopathy market driver impact
Fig. 20 U.S. Diabetic retinopathy market restraint impact
Fig. 21 U.S. Diabetic retinopathy market: type movement analysis
Fig. 22 U.S. Diabetic retinopathy market: type outlook and key takeaways
Fig. 23 Proliferative diabetic retinopathy market estimates and forecast, 2018 - 2030
Fig. 24 Non-proliferative diabetic retinopathy market estimates and forecast, 2018 - 2030
Fig. 25 Diabetic retinopathy market: management movement analysis
Fig. 26 Diabetic retinopathy market: management outlook and key takeaways
Fig. 27 Anti-VEGF market estimates and forecast, 2018 - 2030
Fig. 28 Intraocular Steroid Injection market estimates and forecast, 2018 - 2030
Fig. 29 Laser Surgery market estimates and forecast, 2018 - 2030
Fig. 30 Vitrectomy market estimates and forecast, 2018 - 2030